Ondine Biomedical Reports Low Adverse Event Rate
The LANTERN clinical trial shows high patient tolerance for nasal photodisinfection before surgery.
Updated on Oct. 28, 2026 in Diabetes
Live Poll
Would you feel comfortable undergoing a new, non-FDA approved nasal therapy before a surgical procedure?
Ondine Biomedical reported a 0.31% adverse event rate in its LANTERN clinical trial involving nasal photodisinfection to reduce infection risks. Findings from the 5,188-patient study suggest high patient tolerance and willingness to repeat the treatment.
Why it matters
The study demonstrates that nasal photodisinfection is well-tolerated by patients while potentially reducing surgical site infection risks. These results support the company as it prepares for future regulatory submissions in the United States.
The LANTERN trial enrolled 5,188 patients across 18 hospitals, recording an adverse event rate of 0.31% among 2,543 treated individuals. Data also showed a 40.5% reduction in surgical site infection risk over a 30-day period.
The players
Ondine Biomedical
This life sciences company focuses on light-activated therapies and is currently developing nasal photodisinfection technology.
The details
Nasal photodisinfection utilizes a light-activated agent designed to eliminate bacteria in the nasal cavity prior to surgical procedures. Trial participants reported high satisfaction, with 97.4% describing the process as bearable and 95.4% indicating they would accept it again.
Timeline
In September 2026, the trial met its primary endpoint with a 40.5% lower infection risk.
In October 2026, safety data was presented at the IDWeek conference.
Health Landscape
The presentation of these results at the IDWeek conference highlights the ongoing focus on reducing surgical site infections through specialized medical protocols. This study aligns with a broader trend of integrating light-based therapies into standard preoperative care.
Patients preparing for surgery may eventually see nasal photodisinfection as a standard part of their preoperative routine. However, the treatment is not yet available for general clinical use as it currently lacks FDA approval.
The takeaway
Nasal photodisinfection shows promise as a non-invasive method for improving surgical outcomes without serious side effects. Patients should consult their surgeons regarding approved standard-of-care practices for infection prevention while new technologies undergo regulatory review.
Further reading
Learn more about the latest innovations in Diabetes care and research.
Live Poll
Would you feel comfortable undergoing a new, non-FDA approved nasal therapy before a surgical procedure?
